HK Stock Market Move | EVEREST MED(01952) up more than 3%, Liripoz approved by FDA, expected to submit BLA in the first half of next year in Greater China region.

Everest Medical (01952) rose more than 3%, rising to 3.46% as of the time of publication, reaching 48.44 Hong Kong dollars, with a turnover of 131 million Hong Kong dollars. In terms of news, according to a message from Everest Medical's official WeChat account, on December 17th, the company announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for LIB Therapeutics' cardiovascular product LerocholTM (lerodalcibep-liga) injection, which, in addition to diet control and exercise, is used to lower low-density lipoprotein cholesterol (LDL-C) levels in patients with adult hypercholesterolemia (including heterozygous familial hypercholesterolemia (HeFH)). In December 2025, Everest Medical signed an authorization agreement with Heisen Biotechnology to obtain exclusive permission to conduct subsequent clinical development, registration, and commercialization of LerocholTM (Lerodalcibep) in the Greater China region. LerocholTM is a novel small molecule protein-binding third-generation PCSK9 inhibitor designed to help patients achieve and maintain their LDL-C control goals in the long term. As the first PCSK9 inhibitor fusion protein, LerocholTM has low immunogenicity and outstanding safety. Developed to be more patient-friendly and convenient, LerocholTM can be self-administered by patients with a monthly injection of a small volume subcutaneously, and has long room temperature stability (up to 3 months), allowing patients to choose the time and place of administration at their convenience for easy storage or transport during home or travel. These features make LerocholTM a unique alternative to approved PCSK9 inhibitors.